Previous Close | 102.03 |
Open | 102.39 |
Bid | 106.47 x 800 |
Ask | 108.80 x 1300 |
Day's Range | 102.39 - 110.50 |
52 Week Range | 95.50 - 188.99 |
Volume | |
Avg. Volume | 685,714 |
Market Cap | 26.049B |
Beta (5Y Monthly) | 0.18 |
PE Ratio (TTM) | 5.34 |
EPS (TTM) | 20.34 |
Earnings Date | Nov 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jun 02, 2022 |
1y Target Est | 161.41 |
Subscribe to Yahoo Finance Plus to view Fair Value for BNTX
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) for ages 6 months and older. The updated vaccine will be available in Canada as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. For children 6 months through 4 years of age, the updated vaccine is authorized for administration as a thr